Showing results (1741-1750 of 1,799) with videos related to

Sort By:
Pageof 180
The Journal of Pharmacology and Experimental Therapeutics|August 22, 2006
Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139Thomas A Lanz, Michael J Karmilowicz, Kathleen M Wood, et al.
Journal of Medicinal Chemistry|September 6, 2019
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for TauopathiesHarold G Selnick, J Fred Hess, Cuyue Tang, et al.
Cancer Research|August 15, 2008
Inhibition of the sodium/potassium ATPase impairs N-glycan expression and functionReza Beheshti Zavareh, Ken S Lau, Rose Hurren, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAF<sup>V600</sup>-mutant metastatic melanoma: final analysis and a validated prognostic scoring systemJames Larkin, Michael P Brown, Ana M Arance, et al.
Epilepsy & Behavior : E&B|August 16, 2015
Third International Congress on Epilepsy, Brain and Mind: Part 1Amos D Korczyn, Steven C Schachter, Jana Amlerova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
IEEE Journal of Translational Engineering in Health and Medicine|October 13, 2016
National Institute of Biomedical Imaging and Bioengineering Point-of-Care Technology Research Network: Advancing Precision MedicinePenny Ford Carleton, Steven Schachter, John A Parrish, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaAntoni Ribas, Richard Kefford, Margaret A Marshall, et al.
Molecular Genetics and Metabolism|October 31, 2023
Variant Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal Diseases Variant Curation Expert PanelJennifer L Goldstein, Jennifer McGlaughon, Dona Kanavy, et al.
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
Pageof 180